Generative AI has made it fast and cheap to produce product copy, social posts, and label language at scale. That speed is a liability when the same tools default to bold, medicalized phrasing — especially around appetite, metabolism, and weight, where GLP-1 drugs have reset consumer expectations. A supplement described in language that echoes prescription drug outcomes invites regulatory attention in the US and increasingly in Mexico and other LATAM markets tightening health-claim enforcement.
For brand owners, this shifts where compliance work needs to happen: earlier, and closer to formulation. Claims should be built around what an ingredient and dose can actually support, then checked against current guidance before copy goes anywhere near a label or landing page — not adjusted after a warning letter.
A manufacturing partner that reviews formulation, labeling, and claims together, rather than treating them as separate steps, helps catch these mismatches before launch. In a market where AI can generate confident language faster than anyone can fact-check it, that kind of internal discipline is becoming a real differentiator.